Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of cryptococcal infections
3.2.1.2 Advancements in diagnostic technologies
3.2.1.3 Development of novel antifungal drugs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs
3.2.2.2 Antifungal resistance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Flucytosine
5.3 Amphotericin B
5.4 Fluconazole
5.5 Other treatments
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Intravenous
6.4 Inhalation
Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Branded
7.3 Generic
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Astellas Pharma Inc.
10.2 Abbott Laboratories
10.3 Bausch Health
10.4 Bristol-Myers Squibb Company
10.5 Glenmark Pharmaceuticals
10.6 Janssen Biotech Inc. (Johnson & Johnson)
10.7 Merck & Co., Inc.
10.8 Novartis AG
10.9 NuCare Pharmaceuticals, Inc.
10.10 Pfizer Inc.
10.11 Sigmapharm Laboratories LLC
10.12 Sun Pharmaceutical Industries Ltd.
10.13 Valeant Pharmaceuticals Inc.
10.14 Viamet Pharmaceutical Inc.
